IBDEI0Q3 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11727,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,11727,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,11728,0)
 ;;=N02.3^^46^573^73
 ;;^UTILITY(U,$J,358.3,11728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11728,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11728,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,11728,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,11729,0)
 ;;=N02.4^^46^573^72
 ;;^UTILITY(U,$J,358.3,11729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11729,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11729,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,11729,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,11730,0)
 ;;=N02.5^^46^573^77
 ;;^UTILITY(U,$J,358.3,11730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11730,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,11730,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,11730,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,11731,0)
 ;;=N02.6^^46^573^74
 ;;^UTILITY(U,$J,358.3,11731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11731,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,11731,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,11731,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,11732,0)
 ;;=N02.7^^46^573^75
 ;;^UTILITY(U,$J,358.3,11732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11732,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,11732,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,11732,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,11733,0)
 ;;=N02.8^^46^573^80
 ;;^UTILITY(U,$J,358.3,11733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11733,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,11733,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,11733,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,11734,0)
 ;;=N02.9^^46^573^81
 ;;^UTILITY(U,$J,358.3,11734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11734,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,11734,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,11734,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,11735,0)
 ;;=N03.0^^46^573^18
 ;;^UTILITY(U,$J,358.3,11735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11735,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,11735,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,11735,2)
 ;;=^5015521
 ;;^UTILITY(U,$J,358.3,11736,0)
 ;;=N03.1^^46^573^17
 ;;^UTILITY(U,$J,358.3,11736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11736,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,11736,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,11736,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,11737,0)
 ;;=N03.2^^46^573^14
 ;;^UTILITY(U,$J,358.3,11737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11737,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,11737,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,11737,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,11738,0)
 ;;=N03.3^^46^573^15
 ;;^UTILITY(U,$J,358.3,11738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11738,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,11738,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,11738,2)
 ;;=^5015524
 ;;^UTILITY(U,$J,358.3,11739,0)
 ;;=N03.4^^46^573^13
